Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England

Ultrasound in Obstetrics and Gynecology

Volumn 41, Issue 5, 2013, Pages 526-529

  Morgan, S ^a   Delbarre, A ^b   Ward, P ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

amniocentesis; chorionic villus sampling; combined screening test; Down syndrome; invasive diagnostic procedures; screen positive rate

Indexed keywords

AMNIOCENTESIS; ARTICLE; CHORION VILLUS SAMPLING; CHROMOSOME ANALYSIS; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HEALTH CARE POLICY; HUMAN; PREGNANCY; STATISTICS; UNITED KINGDOM;

AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; CYTOGENETIC ANALYSIS; DOWN SYNDROME; ENGLAND; FEMALE; HEALTH POLICY; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST;

EID: 84876681466     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.12384     Document Type: Review

References (12)

1. Wald NJ, Huttly WJ, Hennessy CF,. Down's syndrome screening in the UK in 1998. Lancet 1999; 354: 1264. (Pubitemid 29469360)
2. Hackshaw AK, Densem J, Wald NJ,. Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free alpha and free beta-hCG. Prenat Diagn 1995; 15: 1125-1130.
3. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM,; SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-77.
4. Wald NJ, Kennard A, Hackshaw A, McGuire A,. Antenatal screening for Down's syndrome. Health Technol Assess 1998; 2: 1-112.
5. Department of Health. NHS Fetal Anomaly Screening Programme-Screening for Down's syndrome: UKNSC Policy recommendations 2007-2010: Model of Best Practice. Department of Health: UK National Screening Committee, 2008.
6. Loughna P, Chitty L, Evans T, Chudleigh T,. Fetal size and dating: charts recommended for clinical obstetric practice. Ultrasound 2009; 17: 160.
7. Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH,. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-346. (Pubitemid 28352196)
8. NHS FASP Annual Report 2006-2008. http://fetalanomaly.screening.nhs.uk/ getdata.php?id=11016 [Accessed 28 November 2012].
9. NHS FASP Annual Report 2010-2011. http://fetalanomaly.screening.nhs.uk/ getdata.php?id=11455 [Accessed 28 November 2012].
10. de Graaf IM, Tijmstra T, Bleker OP, van Lith JMM,. Womens' preference in Down syndrome screening. Prenat Diagn 2002; 22: 624-629. (Pubitemid 34839304)
11. Michailidis GD, Spencer K, Economides DL,. The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's Syndrome. BJOG 2001; 108: 1047-1052. (Pubitemid 32971738)
12. Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A,. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. BMJ 2008; 337: a2547.